Frontiers in Clinical Drug Research - Anti-Cancer Agents is an eBook series intended for pharmaceutical scientists, postgraduate students and researchers seeking updated and critical information for developing clinical trials and devising research plans in anti-cancer research. Reviews in each volume are written by experts in medical oncology and clinical trials research and compile the latest information available on special topics of interest to oncology researchers. The third volume of the eBook series begins with a detailed review of the molecular biology of inhibitors that target EGF-family receptors. This review is divided into two parts that covers extracellular and intracellular molecules. Other reviews cover targeted therapies for cancers such as melanoma, follicular lymphoma and topics such as cancer immunotherapy, apoptosis targeting and the Warburg Effect.

Frontiers in Clinical Drug Research - Anti-Cancer Agents is a book series intended for pharmaceutical scientists, postgraduate students and researchers seeking updated and critical information for developing clinical trials and devising research plans in anti-cancer research. Reviews in each volume are written by experts in medical oncology and clinical trials research and compile the latest information available on special topics of interest to oncology researchers. The fourth volume of the book brings forth reviews on biomarkers and new drugs used for treating gastrointestinal cancer and breast cancer. The volume also covers the topics of adjuvant therapy, cancer nanodrugs and the role of adiponectin and dicycloplatin in cancer therapy.

Frontiers in Clinical Drug Research - Anti-Cancer Agents is a book series intended for pharmaceutical scientists, postgraduate students and researchers seeking updated and critical information for developing clinical trials and devising research plans in anti-cancer research. Reviews in each volume are written by experts in medical oncology and clinical trials research and compile the latest information available on special topics of interest to oncology researchers. The fifth volume of the book features reviews on biochemical inhibitors (second-generation protein kinase Inhibitors, histone deacetylase inhibitors, immune checkpoint inhibitors, EGFR Tyrosine Kinase inhibitors, non-coding RNAs), apoptosis, and physical exercise therapy for cancer patients undergoing chemotherapy. The treatment strategies in this volume cover cancers such as acute myeloid leukemia, gastrointestinal cancer, breast cancer and lung cancer.

Frontiers in Clinical Drug Research - Anti-Cancer Agents is a book series intended for pharmaceutical scientists, postgraduate students and researchers seeking updated and critical information for developing clinical trials and devising research plans in anti-cancer research. Reviews in each volume are written by experts in medical oncology and clinical trials research and compile the latest information available on special topics of interest to oncology and pharmaceutical chemistry researchers. The sixth volume of the book features reviews on these topics: · Immunomodulating Agents in The Treatment of Acute Myeloid Leukemia · Potential Natural Products for Prostate Cancer Management · Inhibition of Key Protein-Protein Interactions by Small Molecules for Cancer Drug Design · Efficacy of Hepatic Arterial Infusion Chemotherapy (HAIC) For Advanced Hepatocellular Carcinoma · Targeting Cancer Stem Cells: Implications in Health and Disease

Frontiers in Clinical Drug Research - Anti-Cancer Agents is a book series intended for pharmaceutical scientists, postgraduate students and researchers seeking updated and critical information for developing clinical trials and devising research plans in anti-cancer research. Reviews in each volume are written by experts in medical oncology and clinical trials research and compile the latest information available on special topics of interest to oncology and pharmaceutical chemistry researchers. The seventh volume of the book features reviews on these topics: </P> · Essential oils and monoterpenes as potential anti-cancer agents </P> · Drug delivery systems and emerging immunotherapeutic strategies for the treatment of glioblastoma </P> · CTDNA in solid tumors </P> · Cholesterol treatments (including Pitavastatin) and their potential in cancer treatment

Frontiers in Clinical Drug Research - Anti-Cancer Agents is a book series intended for pharmaceutical scientists, postgraduate students and researchers seeking updated and critical information for developing clinical trials and devising research plans in anti-cancer research. Reviews in each volume are written by experts in medical oncology and clinical trials research and compile the latest information available on special topics of interest to oncology and pharmaceutical chemistry researchers. The eighth volume of the book features reviews on these topics: - Key data management elements in clinical trials for oncological therapeutics - Prospects for therapeutic targeting of microRNAs in brain tumors - Breast cancer vaccines: current status and future approach - Desmocollin-3 and cancer - MDM2-p53 antagonists under clinical evaluation: a promising cancer targeted therapy for cancer patients harbouring wild-type tp53 - Towards targeted therapy: anticancer agents targeting cell organelle mitochondria - Anticancer therapeutic strategies in gliomas: chemotherapy, immunotherapy, and molecularly targeted therapy in adults

This book focuses on the lung cancer, which is the mostly encountered, and one of the most challenging malignant disease of the world. Worldwide, the annual number of new cases of lung cancer is estimated at more than one million and is expected to increase to ten million in 2025. Fortunately, the political efforts to reduce the use of tobacco are getting increasing attention in many countries and the statistics are now showing the first positive results. Over the last decade there have been several improvements and changes in the lung cancer management. Among the epidemiologic changes we see a change in the histopathologic pattern, with a relative decrease in squamous cell carcinoma and a rise in adenocarcinoma. Much research is attempting to identify biomarkers to predict a high risk for developing lung cancer. This will be important for implementing screening and prevention strategies. There is a steady improvement of the overall management of lung cancer based on an increasing use of combined modality therapy, consisting of surgery, chemotherapy, and radiotherapy applied concurrently or sequentially in early stage disease. Furthermore, new techniques are gaining ground, both within surgery and radiotherapy, and targeted medical therapy is being offered to more and more patients. This book is not intended as a comprehensive textbook, but as a concise summary of advances in lung cancer clinical research and treatment for the clinician. The textbook brings up-to-date information about lung cancer, based on worldwide experience, for the use of the many physicians involved in this field. All of the authors have been selected for their expertise and proven achievement in these challenging fields; I would like to sincerely thank all of them for participating with enthusiasm in this project. I hope that the different contributions will help the readers to fill in the gaps and stimulate them for future developments.

<p></p> Perspectives in Lung Cancer compiles basic and advanced topics on lung cancer pathology and treatment in a single volume. Chapters introduce the reader to chest and lung anatomy followed by the biology of lung cancer. Subsequent chapters delve into diagnostic methods for lung cancer while progressing into treatment options. The book culminates into an explanation of the concept of the Lung Cancer Centre, which is a representation of the editors’ vision for organizing a lung cancer treatment unit. <p></p> Key features: <p></p> *Organises key topics covering both standard and avante-garde topics related to lung cancer <p></p> *All contributions are presented by experts in lung cancer treatment <p></p> *Addresses basic biology of lung cancer <p></p> *Provides information about 3D surgical planning, a relatively new concept in the field of thoracic surgery <p></p> *Addresses the standard method of resection, VATS and Mini VATS <p></p> *Covers the role of radiation and systemic anti-cancer therapies in lung cancer treatment <p></p> *Provides a glimpse of modern methods such as image guided surgery and therapy, laser therapy, and photodynamic therapy <p></p> *Covers the role of palliative care for lung cancer <p></p> *Presents information about a visionary organization of a lung cancer unit and treatment centre. <p></p> The combination of carefully organised chapters covering a wide array of topics makes this reference an essential reference for healthcare professionals interested in acquiring a broad perspective on lung cancer treatment with the goal of improving patient outcomes. <p></p>

Malignant pleural mesothelioma is a life-threatening neoplasm of the mesothelium, the layer of tissue that covers many organs in the human body. The incidence of this type of neoplasm is gradually increasing among the global human population. Mesothelioma prognosis in patients is usually poor and their life expectancy is significantly reduced. This edited monograph presents holistic information about malignant mesothelioma in one volume. Readers will gain knowledge of the etiology, immunopathology of this disease and will understand the rationale for new treatment methods. The initial section of the book gives the historical context of mesothelioma in medicine. Subsequent sections illustrate mesothelioma epidemiology with respect to the problem of asbestos diffusion in different areas of the world such as Europe, The Americas, East Asia, Australia and Africa. This is followed by chapters detailing current information about asbestos and non-asbestos molecular biology and etiopathogenesis, as well as intriguing insights from human genetics and translational medicine. Other sections in this volume focus on clinical information; mesothelioma diagnosis and staging are thoroughly described with a focus on serum biomarkers and pleural liquid cytology. Additional sections provide information on treatment modalities, with one section dedicated to surgical procedures. Malignant Pleural Mesothelioma: Present Status and Future Directions is a comprehensive informational resource with well organized sections, aided by protocol charts, tables and figures. The book is essential for both medical oncology students and specialists who want to augment or update their knowledge about this neoplasm.